Family · Pharmaceutical analytical standards
Nirmatrelvir
An antiviral that blocks the main protease (Mpro) of SARS-CoV-2, the enzyme the virus uses to cut its own proteins and multiply; it is taken together with ritonavir and was authorised in the United States in December 2021 against COVID-19. This family brings together the active ingredient, metabolites, labelled standards and other impurities.
Did you know?Its partner, ritonavir, born as an HIV medicine, does not act on the coronavirus: it blocks the CYP3A enzyme that would break nirmatrelvir down, so raising its levels in the blood.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
